Identifikation und immunologische Charakterisierung von MHC ...

6. Literaturverzeichnis
Molldrem, JJ, Lee, PP, Wang, C., Felio, K., Kantarjian, HM, Champlin, RE and
Davis, MM (2000). Evidence that specific T lymphocytes may participate in the
elimination of chronic myelogenous leukemia. Nat. Med. 6(9): 1018-1023.
Monaco, JJ (1992). A molecular model of MHC class-I-restricted antigen
processing. Immunol. Today 13: 173-179.
Mukherji, B. and MacAlister, TJ (1983). Clonal analysis of cytotoxic T cell
response against human melanoma. J. Exp. Med. 158: 240-245.
Mumberg, D., Monach, PA, Wanderling, S., Philip, M., Toledano, AY,
Schreiber, RD and Schreiber, H. (1999). CD4(+) T cells eliminate MHC class II-
negative cancer cells in vivo by indirect effects of IFN-gamma. Proc. Natl.
Acad. Sci. U S A 96(15): 8633-8638.
Nestle, FO, Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G.
and Schadendorf, D. (1998). Vaccination of melanoma patients with peptide-
or tumor lysate-pulsed dendritic cells [see comments]. Nat. Med. 4: 328-332.
Niles, JL, McCluskey, RT, Ahmad, MF and Arnaout, MA (1989). Wegener's
granulomatosis autoantigen is a novel neutrophil serine proteinase. Blood
74(6): 1888-1893.
Novellino, L., Castelli, C. and Parmiani, G. (2005). A listing of human tumor
antigens recognized by T-cells: March 2004 update. Cancer Immunol.
Immunother. 54: 187-207.
North, RJ and Awwad, M. (1990). Elimination of cycling CD4+ suppressor
T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause
regression of an advanced lymphoma. Immunology 71(1): 90-95.
113